ライフサイエンスコーパス: antiphospholipid

1 Antiphospholipid Ab have been shown to promote thrombosi

2 vity of eight patient-derived monoclonal IgG antiphospholipid Ab with FXa and the presence of IgG ant

3 ty in the antiphospholipid syndrome (APS) is antiphospholipid Ab-mediated upregulation of tissue fact

4 In the antiphospholipid syndrome (APS), antiphospholipid Abs (aPL) bind to anionic phospholipids

5 We previously reported that some human antiphospholipid Abs (aPL) in patients with the antiphos

6 Antiphospholipid Abs (APLAs) are associated with thrombo

7 f thrombotic events among women positive for antiphospholipid Abs (n = 517), women carrying the F5 60

8 eported; both represent the major subsets of antiphospholipid Abs present in antiphospholipid syndrom

9 eta(2)GPI) is the major antigenic target for antiphospholipid Abs.

10 munosorbent assay (ELISA) and immunoblot for antiphospholipid and A2 antibodies.

11 Other autoreactive IgM antibodies, such as antiphospholipid and anti-Sm, did not alter the patholog

12 One mechanism by which circulating antiphospholipid/anti-beta2GPI antibodies may promote th

13 erosclerosis have an increased prevalence of antiphospholipid antibodies (aPL) and antibodies to oxid

14 Although antiphospholipid antibodies (aPL) are associated with ar

15 Pathogenic antiphospholipid antibodies (aPL) bind the self antigen

16 In antiphospholipid syndrome (APS), antiphospholipid antibodies (aPL) binding to beta2 glyco

17 The presence of antiphospholipid antibodies (aPL) has been associated wi

18 Antiphospholipid antibodies (aPL) have been shown to ind

19 Antiphospholipid antibodies (aPL) have thrombogenic prop

20 To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the a

21 phospholipid syndrome (APS), suggesting that antiphospholipid antibodies (aPL) may bind platelets, ca

22 Serum antiphospholipid antibodies (aPL) were identified by ant

23 ients had APS, 24 patients were positive for antiphospholipid antibodies (aPL), and 19 patients had S

24 ion with these mutations and the presence of antiphospholipid antibodies (aPL), lupus anticoagulant (

25 a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnanc

26 hat has been associated with the presence of antiphospholipid antibodies (aPL).

27 poorly known, particularly in the absence of antiphospholipid antibodies (APL).

28 d laboratory confirmation of the presence of antiphospholipid antibodies (aPL).

29 Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a fi

30 Patients with antiphospholipid antibodies (APLAs) are at increased ris

31 is and recurrent fetal loss in patients with antiphospholipid antibodies (APLAs).

32 recurrent pregnancy loss in the presence of antiphospholipid antibodies (APLAs).

33 Fetal loss induced by antiphospholipid antibodies (aPLs) in mice is a compleme

34 There are few data on the relationship of antiphospholipid antibodies (aPLs) to pathologically pro

35 (P = 0.04) and were also more likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0

36 Antiphospholipid antibodies and CRP support the role of

37 mbocytopenia associated with the presence of antiphospholipid antibodies and persistently positive an

38 lar endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement sy

39 mbotic status of APS patients induced by IgG-antiphospholipid antibodies and the beneficial effects o

40 Antiphospholipid antibodies are associated with arterial

41 Patients who have circulating antiphospholipid antibodies are at risk for major abdomi

42 Antiphospholipid antibodies are commonly found in patien

43 d detected in clinical laboratory assays for antiphospholipid antibodies are directed against prothro

44 (n = 513; LMWH + LDA) and women negative for antiphospholipid antibodies as controls (n = 791; no tre

45 n with aspirin is justified in patients with antiphospholipid antibodies but without a prior history

46 Antiphospholipid antibodies can be detected in roughly 5

47 The field of antiphospholipid antibodies continues to evolve, with ma

48 a component and suggest that the epitopes of antiphospholipid antibodies could include CL or oxidized

49 bset of periodontitis patients with elevated antiphospholipid antibodies could represent a subgroup a

50 Anticoagulation, prednisone dose, and antiphospholipid antibodies did not significantly impact

51 Antiphospholipid antibodies disrupt AnxA5 binding, there

52 The antiphospholipid antibodies found in this syndrome are d

53 gs of yellow scleral plaques and circulating antiphospholipid antibodies have been proposed as marker

54 onucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent.

55 The role of antiphospholipid antibodies in ocular disease has receiv

56 PS) is defined by the persistent presence of antiphospholipid antibodies in patients with a history o

57 een conducted to determine the prevalence of antiphospholipid antibodies in patients with retinal vas

58 Antiphospholipid antibodies in SLE are associated with m

59 Antiphospholipid antibodies including anticardiolipin an

60 of thrombosis and gestational morbidity with antiphospholipid antibodies is termed antiphospholipid s

61 e setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occa

62 The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway w

63 HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5

64 otein I (beta(2)-GPI) is a major antigen for antiphospholipid antibodies present in patients with the

65 Antiphospholipid antibodies should be sought in all pati

66 r V Leiden, prothrombin 20210A mutation, and antiphospholipid antibodies significantly increases a pa

67 the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as

68 actions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and

69 rrent pregnancy loss includes measurement of antiphospholipid antibodies under the perception that th

70 Rates of antiphospholipid antibodies were low, comparable to thos

71 No antiphospholipid antibodies were present in the patient'

72 Antiphospholipid antibodies were present(defined as IgG

73 Eighteen women with antiphospholipid antibodies who had refractory pregnancy

74 ion on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirol

75 n I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalyti

76 c lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but a

77 re corticosteroid treatment, the presence of antiphospholipid antibodies, and acute thrombocytopenia.

78 limitations of existing laboratory tests for antiphospholipid antibodies, and the absence of evidence

79 Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibo

80 y of stroke, migraine with aura, circulating antiphospholipid antibodies, discontinuation of antiplat

81 ment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged.

82 thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-beta2-glycop

83 patients with key clinical manifestations of antiphospholipid antibodies, including patients with ant

84 ion discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of

85 ll lines, wherein HCQ reduced the binding of antiphospholipid antibodies, increased cell-surface AnxA

86 n of disease, hypertension, body mass index, antiphospholipid antibodies, kidney disease, acute throm

87 or V antibody not related to the presence of antiphospholipid antibodies, which is responsible for th

88 or at risk of, thrombosis in the setting of antiphospholipid antibodies.

89 cular complications of lupus associated with antiphospholipid antibodies.

90 ffective for nonthrombotic manifestations of antiphospholipid antibodies.

91 coprotein I (beta2GPI), the main antigen for antiphospholipid antibodies.

92 disease activity, emotional disturbance, and antiphospholipid antibodies.

93 recurrent pregnancy failure associated with antiphospholipid antibodies.

94 ity in the presence of persistently positive antiphospholipid antibodies.

95 hrombotic risk in asymptomatic patients with antiphospholipid antibodies.

96 al anticoagulant and fibrinolytic systems by antiphospholipid antibodies.

97 factor VII mutation, factor II mutation, and antiphospholipid antibodies.

98 ished by the 13th International Committee on Antiphospholipid Antibodies.

99 w that ApoER2 is involved in pathogenesis of antiphospholipids antibodies.

100 to PON1 activity, SLE risk, lupus nephritis, antiphospholipid antibody (aPL) positivity, and carotid

101 action of WIG in an in vivo murine model of antiphospholipid antibody (aPL)-induced thrombosis and e

102 sis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (th

103 y was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)-positive patients with n

104 physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.

105 Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complica

106 patients, and 0 of 5 cycles in 2 women with antiphospholipid antibody (without SLE or primary APS) r

107 The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA)

108 ress with regard to the relationship between antiphospholipid antibody and its target, beta-2-glycopr

109 Antiphospholipid antibody profiles and clinical outcome

110 Antiphospholipid antibody syndrome (APAS) is characteriz

111 End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high

112 Antiphospholipid antibody syndrome (APS) is a complex au

113 Patients with the antiphospholipid antibody syndrome (APS) often experienc

114 es that were all isolated from patients with antiphospholipid antibody syndrome (APS); testing was al

115 New antibody tests for antiphospholipid antibody syndrome are available with in

116 understanding of the pathophysiology behind antiphospholipid antibody syndrome has led to novel appr

117 idelines for the treatment and management of antiphospholipid antibody syndrome have been established

118 The diagnostic criteria of antiphospholipid antibody syndrome have been reviewed an

119 The antiphospholipid antibody syndrome is an important cause

120 Antiphospholipid antibody syndrome with valvular vegetat

121 iolipin (anti-CL) antibodies, diagnostic for antiphospholipid antibody syndrome, are associated with

122 d cause valvular vegetations associated with antiphospholipid antibody syndrome, which would be a new

123 pholipid antibodies, including patients with antiphospholipid antibody syndrome.

124 e appropriate laboratory results make up the antiphospholipid antibody syndrome.

125 id-binding protein and an autoantigen in the antiphospholipid antibody syndrome.

126 ociated with thrombosis in patients with the antiphospholipid antibody syndrome.

127 ave also updated information about pediatric antiphospholipid antibody syndrome.

128 Routine laboratory, autoantibody, and antiphospholipid antibody testing was performed in the h

129 reincubation of healthy monocytes before IgG-antiphospholipid antibody treatment decreased oxidative

130 olytic anemia, anti-double-stranded DNA, and antiphospholipid antibody were associated with thrombocy

131 levant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/

132 utcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es)

133 r assessment in the management of refractory antiphospholipid antibody-related pregnancy loss(es), al

134 cardiac foramen ovale, or elevated levels of antiphospholipid antibody.

135 ctive protein (CRP), and the presence of any antiphospholipid antibody.

136 eutrophil cytoplasmic, antiendothelial cell, antiphospholipid/anticardiolipin and antithyroid antibod

137 nancy loss and thrombosis in the presence of antiphospholipid (aPL) Ab's.

138 Antiphospholipid (aPL) Abs are associated with thrombosi

139 , and vascular thrombosis in the presence of antiphospholipid (aPL) Abs.

140 recurrent pregnancy loss in the presence of antiphospholipid (aPL) antibodies and is generally treat

141 Antiphospholipid (aPL) antibodies are associated with th

142 Fetal loss in patients with antiphospholipid (aPL) antibodies has been ascribed to t

143 Antiphospholipid (aPL) antibodies recognize receptor-bou

144 Using different mouse monoclonal and human antiphospholipid (aPL) antibodies, we developed a new an

145 hrombocytopenia occurring in the presence of antiphospholipid (aPL) antibodies.

146 The antiphospholipid (aPL) antibody syndrome is an autoimmun

147 Recent studies have shown that antiphospholipid (aPL) enhances expression of intercellu

148 Recently, human antiphospholipid (aPL) monoclonal antibodies (mAbs) have

149 iated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal

150 The antiphospholipid (aPL) syndrome is an acquired autoimmun

151 The antiphospholipid (aPL) syndrome is an autoimmune conditi

152 Antiphospholipid (aPL)/anti-beta(2) glycoprotein I (anti

153 stically significant, reductions of clinical antiphospholipid assays.

154 of systematically testing for C. burnetii in antiphospholipid-associated cardiac valve disease, and p

155 Antiphospholipid autoantibodies (aPLs) are prevalent in

156 s and gestational morbidity in patients with antiphospholipid autoantibodies (aPLs).

157 These findings identify antiphospholipid autoantibodies as a potential patient-s

158 central nervous system disorder, high-titer antiphospholipid autoantibodies, and autoimmune cytopeni

159 antinuclear antibodies: one had anti-RNP and antiphospholipid autoantibodies, and the other had anti-

160 e, and performing early echocardiography and antiphospholipid dosages in patients with acute Q fever.

161 Similar reversals of antiphospholipid-induced abnormalities were measured on

162 In conclusion, HCQ reversed antiphospholipid-mediated disruptions of AnxA5 on PLBs a

163 s are reported in approximately one third of antiphospholipid-positive patients.

164 A high percentage of patients with antiphospholipid syndrome (41%) and systemic lupus eryth

165 y complications: a mouse model of obstetrics antiphospholipid syndrome (APS) and a mouse model of pre

166 d with thrombosis in patients diagnosed with antiphospholipid syndrome (APS) and enhance thrombus for

167 Male (NZW x BXSB)F(1) mice develop antiphospholipid syndrome (APS) and proliferative glomer

168 Patients with antiphospholipid syndrome (APS) are at a high risk of de

169 Pregnant women with antiphospholipid syndrome (APS) are at a high risk of ob

170 iphospholipid Abs (aPL) in patients with the antiphospholipid syndrome (APS) bind to the homologous e

171 Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) can be associated with s

172 Xa reactive IgG isolated from patients with antiphospholipid syndrome (APS) display higher avidity b

173 lar weight heparin [LDA+LMWH]) for obstetric antiphospholipid syndrome (APS) does not prevent life-th

174 the pathogenesis, diagnosis and treatment of antiphospholipid syndrome (APS) from current literature.

175 The classification criteria for both SLE and antiphospholipid syndrome (APS) have been updated, and u

176 The antiphospholipid syndrome (APS) is a systemic autoimmune

177 Antiphospholipid syndrome (APS) is an autoimmune disease

178 Antiphospholipid syndrome (APS) is an autoimmune disorde

179 major mechanism of hypercoagulability in the antiphospholipid syndrome (APS) is antiphospholipid Ab-m

180 The antiphospholipid syndrome (APS) is characterized by recu

181 The antiphospholipid syndrome (APS) is characterized by recu

182 Antiphospholipid syndrome (APS) is characterized by recu

183 Antiphospholipid syndrome (APS) is defined by recurrent

184 The antiphospholipid syndrome (APS) is defined by the persis

185 The antiphospholipid syndrome (APS) is defined by thrombosis

186 Antiphospholipid syndrome (APS) is defined by thrombosis

187 r pregnancy loss and either purely obstetric antiphospholipid syndrome (APS) or inherited thrombophil

188 olipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformation

189 e prothrombotic or proinflammatory status of antiphospholipid syndrome (APS) remain unknown.

190 ibodies test can identify some patients with antiphospholipid syndrome (APS) that are negative for ot

191 for women with the purely obstetric form of antiphospholipid syndrome (APS) treated with prophylacti

192 mmunoglobulin G (IgG) from patients with the antiphospholipid syndrome (APS) upon monocyte activation

193 Women with antiphospholipid syndrome (APS), a condition characteriz

194 In the antiphospholipid syndrome (APS), antiphospholipid Abs (a

195 In antiphospholipid syndrome (APS), antiphospholipid antibo

196 e clinical phenotype, including catastrophic antiphospholipid syndrome (APS), atypical presentations

197 linked to autoimmune disorders, particularly antiphospholipid syndrome (APS), in which autoantibodies

198 sis and thrombocytopenia are features of the antiphospholipid syndrome (APS), suggesting that antipho

199 ribute to thrombosis and miscarriages in the antiphospholipid syndrome (APS).

200 e the mid-1980s for diagnosing patients with antiphospholipid syndrome (APS).

201 y with antiphospholipid antibodies is termed antiphospholipid syndrome (APS).

202 to promote thrombosis and fetal loss in the antiphospholipid syndrome (APS).

203 IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS).

204 ) is the most common disease associated with antiphospholipid syndrome (APS).

205 ctly contribute to hypercoagulability in the antiphospholipid syndrome (APS).

206 Ab (aPL) and thrombosis is recognized as the antiphospholipid syndrome (APS).

207 )GPI) appear to be a critical feature of the antiphospholipid syndrome (APS).

208 b (aCL), and thrombosis is recognized as the antiphospholipid syndrome (APS).

209 manifestations is now well-recognized as the antiphospholipid syndrome (APS).

210 with systemic lupus erythematosus or primary antiphospholipid syndrome (APS).

211 (designated IS6) from a patient with primary antiphospholipid syndrome (APS).

212 the effect of antibodies from patients with antiphospholipid syndrome (APS).

213 patients with non-criteria manifestations of antiphospholipid syndrome (APS).

214 Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal

215 Catastrophic antiphospholipid syndrome (CAPS) is characterized by his

216 e either purified IgG from patients with the antiphospholipid syndrome (IgG-APS) or normal IgG from h

217 G (IgG) isolated from either a patient with antiphospholipid syndrome (IgG-APS), a healthy control s

218 by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study Group give us

219 stemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (primary APS) undergoing OI/IV

220 ere treated with IgG aPL (from patients with antiphospholipid syndrome [APS]) or with control IgG (fr

221 ective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboemb

222 ive immune responses with innate immunity in antiphospholipid syndrome and systemic lupus erythematos

223 s, such as heparin-induced thrombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopeni

224 otic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic com

225 pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate ther

226 ndrome patient sera are not only a marker of antiphospholipid syndrome but are directly involved in t

227 dies purified from the sera of patients with antiphospholipid syndrome complicated by thrombosis grea

228 NT FINDINGS: Although the pathophysiology of antiphospholipid syndrome continues to be poorly underst

229 the antibodies and antigens involved in the antiphospholipid syndrome has provided many new insights

230 me that involves the injection of high-titer antiphospholipid syndrome human serum, complement activa

231 hile the 956A allele was associated with the antiphospholipid syndrome in patients with SLE (P = 0.00

232 s in the glomeruli, recapitulating the human antiphospholipid syndrome in these mice.

233 controversial issues in the treatment of the antiphospholipid syndrome include the use of less intens

234 Antiphospholipid syndrome includes elevation of either t

235 The antiphospholipid syndrome is a disorder of recurrent thr

236 The antiphospholipid syndrome is a major feature of systemic

237 PURPOSE OF REVIEW: Antiphospholipid syndrome is a rare cause of ocular vaso

238 Antiphospholipid syndrome is an autoimmune disease chara

239 Antiphospholipid syndrome is characterized by recurrent

240 Antiphospholipid syndrome is characterized by thrombosis

241 The antiphospholipid syndrome is characterized by thrombosis

242 Antiphospholipid syndrome is characterized by thrombosis

243 The antiphospholipid syndrome is characterized clinically by

244 Diagnosis and treatment of antiphospholipid syndrome is difficult, however, because

245 m, but whether it is useful in patients with antiphospholipid syndrome is uncertain.

246 f thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain.

247 ate clinical manifestations in patients with antiphospholipid syndrome may be established.

248 f the thrombin-reactive aCL in patients with antiphospholipid syndrome may bind to PC and APC.

249 rating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications

250 Patients with antiphospholipid syndrome nephropathy who required trans

251 essels of patients with primary or secondary antiphospholipid syndrome nephropathy.

252 related to systemic lupus erythematosus and antiphospholipid syndrome occur in association with mult

253 that anti-beta(2)-GP1 IgG autoantibodies in antiphospholipid syndrome patient sera are not only a ma

254 anti-cardiolipin mAbs derived from a primary antiphospholipid syndrome patient.

255 anticoagulation are similarly protective in antiphospholipid syndrome patients after the first throm

256 Catastrophic antiphospholipid syndrome patients usually receive a com

257 r subsets of antiphospholipid Abs present in antiphospholipid syndrome patients.

258 cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the p

259 In the mouse model of antiphospholipid syndrome that involves the injection of

260 a(2)-GP1 autoantibodies from 3 patients with antiphospholipid syndrome were affinity-purified using h

261 in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for p

262 cted at a French referral center for SLE and antiphospholipid syndrome, 24 patients with SLE, with a

263 expansions in JPH3, a fourth patient with an antiphospholipid syndrome, and a fifth patient with B12

264 nts with systemic lupus erythematosus or the antiphospholipid syndrome, and a subset of such antibodi

265 y artery disease, peripheral artery disease, antiphospholipid syndrome, and cancer.

266 rs such as heparin-induced thrombocytopenia, antiphospholipid syndrome, and therapy with asparaginase

267 ts with systemic lupus erythematosus and the antiphospholipid syndrome, are associated with adverse p

268 lar risks, lupus nephritis, CNS disease, the antiphospholipid syndrome, assessment of disease activit

269 is is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are

270 rs, such as rheumatoid arthritis and primary antiphospholipid syndrome, reacted infrequently.

271 ative colitis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren syndrome, myasthenia

272 th the spectrum of clinical manifestation of antiphospholipid syndrome, the diagnostic criteria of th

273 n documented as a biomarker for diagnosis of antiphospholipid syndrome, their direct role in the path

274 of the immunology and pathophysiology of the antiphospholipid syndrome, treating this condition remai

275 f polyclonal IgG purified from patients with antiphospholipid syndrome, using both solid-phase and fl

276 roquine and the statins for the treatment of antiphospholipid syndrome-associated clinical manifestat

277 ay hold promise as a therapeutic approach to antiphospholipid syndrome-associated pregnancy complicat

278 for therapy to prevent pregnancy loss in the antiphospholipid syndrome.

279 contribute to the prothrombotic diathesis in antiphospholipid syndrome.

280 criteria for diagnosis and treatment of the antiphospholipid syndrome.

281 ctively bound IgG derived from patients with antiphospholipid syndrome.

282 re particularly relevant to Ags important in antiphospholipid syndrome.

283 ipid antibodies present in patients with the antiphospholipid syndrome.

284 ologic findings in patients with established antiphospholipid syndrome.

285 excluded patients with malignant disease and antiphospholipid syndrome.

286 ogenic aPL may be generated in patients with antiphospholipid syndrome.

287 eye is involved frequently in patients with antiphospholipid syndrome.

288 anticoagulant, or a history compatible with antiphospholipid syndrome.

289 sy specimens from patients with catastrophic antiphospholipid syndrome.

290 , they are useful laboratory markers for the antiphospholipid syndrome.

291 specimens from persons who had catastrophic antiphospholipid syndrome.

292 in the vascular lesions associated with the antiphospholipid syndrome.

293 mus in kidney-transplant recipients with the antiphospholipid syndrome.

294 ose with systemic lupus erythematosus and/or antiphospholipid syndrome.

295 nt state in these diseases as well as in the antiphospholipid syndrome.

296 nia, thrombotic thrombocytopenia purpura and antiphospholipid syndrome.

297 dies promote atherosclerosis in persons with antiphospholipid syndrome.

298 a and beta(2)-glycoprotein-I (beta(2)GPI) in antiphospholipid syndrome.

299 new targets for therapeutic intervention in antiphospholipid syndrome.

300 s positively correlated with the symptoms of antiphospholipid syndromes (APS), including thrombosis a